NCT05897099NARecruiting

Comprehensive HIV and Harm Prevention Via Telehealth

University of Miami

Start Date

10/7/2024

Completion Date

5/31/2028

Summary

The purpose of this study is to test 2 different ways to offer medications to prevent human immunodeficiency virus (HIV), cure hepatitis C virus (HCV) (if applicable) and treat substance use disorder (if desired) in people who inject drugs.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * age 18 or older * able to speak English or Spanish * willing and able to sign informed consent, provide locator information and medical records release * non-reactive result on rapid HIV test * use of SSP to exchange syringes 2 times in the past 3 months * planning to stay in the area for 12 months Exclusion Criteria: * reactive HIV test * currently on medications for opioid use disorder (MOUD) by urine drug screen * currently on PrEP by self-report * Principal or site investigator discretion * currently in prison or jail * current enrollment in Clinical Trials Network 121 * receipt of tele-harm reduction in previous 3 months * signs or symptoms of acute HIV infection

Interventions

BEHAVIORAL

Comprehensive Tele-harm Reduction

BEHAVIORAL

Off-site Linkage to HIV Prevention

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

HIV Infections

Locations

IDEA Miami

Miami, Florida 33136

United States

IDEA Syringe Services Program

Miami, Florida 33136

United States